FDA cybersecurity deficiency letter response services for medical device manufacturers.
Whether the FDA called it a Deficiency Letter, an AINN (Additional Information Needed Notification), or an Additional Information Request - the cybersecurity findings are the same set of gaps we close every week. Senior US-based team, eSTAR-ready response, mutual NDA before the call, fixed-fee quote within 24 hours of the call.
Free 30-min call · Senior US expert · Mutual NDA before the call
Last updated
“Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device.”
Anna Norman, VP of Product, InfoBionic.Ai
Trusted by medical device teams worldwide
Premarket to postmarket. One senior team owns every cybersecurity artifact the FDA reviewer will open.
Each FDA finding gets a numbered response with the exact artifact, page reference, and Section 524B citation that closes it.
Same playbook whether the FDA calls it an AINN, additional information request, or deficiency letter - we've responded to all of them.
Refreshed SPDX or CycloneDX SBOM with VEX statements addressing any CVE concerns the FDA raised.
We pen-test only what the FDA asked about - fastest path to closing the file, not padding the invoice.
Structured exactly the way FDA cybersecurity reviewers expect: finding → response → evidence → location in submission.
One quote covers the response and any follow-up exchanges until the cybersecurity file is closed. No retest invoices.
We've responded to hundreds of FDA cybersecurity deficiency letters. The findings cluster into the same handful of categories - these are the ones we close every week.
Reviewer asks for a machine-readable SBOM (SPDX or CycloneDX) with VEX statements addressing every flagged CVE. We rebuild it to FDA expectations.
STRIDE-based threat model missing data-flow diagrams, trust boundaries, or mitigations traced to design controls. We refresh it end-to-end.
Reviewer wants vulnerability testing, fuzz testing, or penetration testing scoped to the device's actual interfaces. We run a targeted retest, not a full re-scope.
Missing traceability between Section 524B(b)(1)-(3) requirements and submission artifacts. We deliver a refreshed matrix the reviewer can check off.
Secure product development framework documentation that doesn't show evidence of execution. We pair the SPDF with artifacts that prove it ran.
Reviewer wants a credible coordinated vulnerability disclosure (CVD) process, SBOM monitoring plan, and patch cadence. We document what you'll actually do.
What you actually get versus a generic regulatory consultant or re-spinning the cybersecurity attachment in-house against the 180-day clock.
| Capability | Blue Goat Cyber | Generic regulatory consultant | In-house |
|---|---|---|---|
| Cyber-deficiency-specific experience | Hundreds of AI/deficiency responses closed | Treats cyber as a regulatory writing task | First time under deadline pressure |
| Turnaround inside 180-day clock | Reviewer-ready package in 2-4 weeks | Hourly, drifts with scope | Competes with engineering work |
| Maps response point-by-point to the letter | Mirrors reviewer's exact ordering | General rewrite, gaps remain | Built from scratch, easy to miss items |
| eSTAR-attachable cover letter + evidence | Drop-in for resubmission | Word docs that need reformatting | Reformatted each time |
| Pricing model | Fixed fee, unlimited revisions until accepted | Hourly + change orders | Hidden internal cost |
We sign a mutual NDA before the initial call, then walk through your submission, the FDA findings, and the path to close them.
You receive a point-by-point response strategy mapped to Section 524B and the FDA February 2026 final guidance, plus a fixed-fee quote.
Updated SPDF, SBOM/VEX, threat model, targeted pen test, and cover letter - formatted the way FDA cybersecurity reviewers expect in eSTAR.
"Their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind - it gave us confidence that we were submitting exactly what reviewers want to see."
"The organized documentation, perfectly formatted for eSTAR, saves us countless hours. Their expertise and smooth process mean we can focus on our product, not the paperwork."
If the FDA raises a cybersecurity deficiency, we fix it at no additional cost. 250+ FDA submissions, zero cybersecurity rejections to date.
We sign a mutual NDA before the initial call so you can share device details, architecture, and FDA correspondence freely.
No sales pressure. After the call, you get a concrete written strategy mapped to Section 524B and the FDA February 2026 final guidance.
Senior-led delivery on every FDA-facing artifact. No offshoring, no hourly billing. Unlimited revisions. Every artifact is eSTAR-ready.
Who you're talking to
MBA, CISSP · U.S. Air Force Academy graduate · 30+ years in cybersecurity
Christian leads the senior medical device cybersecurity team behind 250+ FDA submissions, zero cybersecurity rejections. Author of three books including Medical Device Cybersecurity: An In-Depth Guide.
30-minute call with a senior medical device cybersecurity expert. Mutual NDA signed before the call. Fixed-fee quote to close the file within 24 hours of the call.
What triggers deficiency letters, SIRs, RTAs, and hold letters, and how manufacturers respond without losing submission cycles.
The four cybersecurity deficiency patterns the FDA flags most often in 510(k) submissions - incomplete SBOMs, thin threat models, scoped-down pen tests.
Read the analysisHow the FDA distinguishes Major from Minor cybersecurity deficiencies in 510(k) and PMA reviews, the response-window difference, and how to keep findings.
Read the analysisFDA Deficiency Letter, RTA, and Hold Letter explained side-by-side. What each one means, the clock impact, and how to respond without losing months.
Read the analysisFDA Submission Issue Request (SIR) response strategy for cybersecurity: eSTAR prep checklist, common 524B gaps, and how to answer without restarting review.
Read the analysis